Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000049348 | SCV000220914 | likely pathogenic | Aspartylglucosaminuria | 2014-11-25 | criteria provided, single submitter | literature only | |
Eurofins Ntd Llc |
RCV000724147 | SCV000227001 | pathogenic | not provided | 2015-02-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000049348 | SCV001208677 | pathogenic | Aspartylglucosaminuria | 2023-04-28 | criteria provided, single submitter | clinical testing | This premature translational stop signal has been observed in individuals with aspartylglucosaminuria (PMID: 7627186). ClinVar contains an entry for this variant (Variation ID: 55939). For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Glu67Alafs*3) in the AGA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGA are known to be pathogenic (PMID: 7627186, 11309371). This variant is present in population databases (rs386833420, gnomAD 0.002%). |
Centre for Mendelian Genomics, |
RCV000049348 | SCV001369986 | pathogenic | Aspartylglucosaminuria | 2019-01-15 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. |
Fulgent Genetics, |
RCV000049348 | SCV002809359 | pathogenic | Aspartylglucosaminuria | 2024-03-18 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000049348 | SCV004217593 | pathogenic | Aspartylglucosaminuria | 2024-02-23 | criteria provided, single submitter | clinical testing | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049348 | SCV000081780 | probable-pathogenic | Aspartylglucosaminuria | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000049348 | SCV002084893 | pathogenic | Aspartylglucosaminuria | 2020-08-17 | no assertion criteria provided | clinical testing |